Montelukast TGA safety alert

The TGA is adding extra safety information to all montelukast products to highlight existing warnings about serious neuropsychiatric effects that have been reported in patients taking this medicine. The information includes a new boxed warning on the Product Information and Consumer Medicine Information (CMI) for doctors and patients on what to do if neuropsychiatric reactions occur. Health professionals are advised to: look out for such reactions in patients taking montelukast and discontinue treatment if new or worsening symptoms occur, advise patients and carers to be alert for changes in behaviour, and consider providing the CMI to remind patients of these effects. Read more via: https://www.tga.gov.au/news/safety-alerts/montelukast-safety-alert.